The Leucocyte Telomere Length, GSTM1 and GSTT1 Null Genotypes and the Risk of Chronic Obstructive Pulmonary Disease

Tanya Tacheva ¹, Shanbeh Zienolddiny-Narui ², Dimo Dimov ¹, Denitsa Vlaykova ¹, Iva Miteva ³ and Tatyana Vlaykova ¹,4,*

¹ Department of Medical Chemistry and Biochemistry, Medical Faculty, Trakia University, 6000 Stara Zagora, Bulgaria
² Section for Toxicology and Biological Work Environment, National Institute of Occupational Health, NO-036 Oslo, Norway
³ Department of Occupational Medicine, Faculty of Public Health, Medical University-Sofia, 1431 Sofia, Bulgaria
⁴ Department of Medical Biochemistry, Medical University-Plovdiv, 4002 Plovdiv, Bulgaria
* Correspondence: tatyana.vlaykova@trakia.uni.bg

Simple Summary: Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation and oxidative stress, both in the airways and blood, and in other organs. Elevated oxidative stress and inflammation have been reported to affect leucocyte telomere length (LTL). We explored the link between GSTM1 and GSTT1 gene polymorphisms, LTL and COPD risk. For GSTM1 and GSTT1, we genotyped 152 COPD patients and 131 non-affected controls, while for TL, we assessed 91 patients and 88 controls. There was a significant difference in GSTM1 null genotype frequency between the patients and controls (0.59 vs. 0.38, p ≤ 0.000), but such was not found for GSTT1 (p = 0.192). COPD patients carrying the GSTM1 null genotype had shorter telomeres compared to those carrying the non-null genotype (15,720 bp vs. 22,442 bp, p = 0.008); and in controls, the opposite occurred (31,354 bp vs. 17,800 bp, p = 0.020). According to our results GSTM1, but not GSTT1, null genotypes might play role in leucocyte telomere shortening, and thus be involved in the pathogenesis of COPD.

Abstract: Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation and oxidative stress both in the airways and blood and other organs. Elevated oxidative stress and inflammation have been reported to affect leucocyte telomere length (LTL). Glutathione S-transferase (GST) enzymes are a large family of xenobiotic-metabolizing enzymes that utilize different ROS products. We aimed to explore the link between GSTM1 and GSTT1 gene polymorphisms, LTL and COPD risk. For GSTM1, we genotyped 152 COPD patients and 131 non-affected controls; for GSTT1, we genotyped 149 COPD patients and 130 controls. We were able to assess TL for 91 patients and 88 controls. There was a significant difference in both groups remained (GSTM1 0.020), but such was not found for GSTT1 (p = 0.192). When combining both polymorphisms, we obtained a significantly greater presence of at least one null genotype among patients (0.12 vs. 0.05, p = 0.027). An association between GSTT1 and LTL was not found. COPD patients carrying the GSTM1 null genotype had shorter telomeres compared to those carrying the non-null genotype (15,720 bp vs. 22,442 bp, p = 0.008); as for the controls, it was the opposite (31,354 bp vs. 17,800 bp, p = 0.020). The significance in both groups remained when combining GSTM1 and GSTT1 (COPD (at least one null) 16,409 bp vs. COPD (non-null) 22,092 bp, p = 0.029; control (at least one null) 29,666 bp vs. control (non-null) 16,370 bp, p = 0.027). The total glutathione level in GSTM1 non-null controls was higher compared to the null genotype (15.39 ng/mL vs. 5.53 ng/mL, p = 0.002). In COPD patients, we found no association (p = 0.301). In conclusion, according to our results, GSTM1, but not GSTT1, null genotypes might play a role in leucocyte telomere shortening, and thus be involved in the pathogenesis of COPD.
1. Introduction

Chronic obstructive pulmonary disease (COPD) is one of the most common diseases of the airways, and possesses a large number of phenotypes [1]. It is characterized by irreversible airflow obstruction due to fibrosis of the small airways, and mucus secretion and air trapping as a result of emphysema. Many risk factors play a role in the pathogenesis of this disease, but the most common are smoking and environmental and indoor pollution (e.g., biomass exposure) [2]. The inhalation of tobacco smoke and other exogenous particles result in the formation of ROS directly or indirectly. Tobacco smoke is rich in ROS, as both the gas and tar phases contain large amounts of free radicals. ROS in the gas phase are generated during the combustion of tobacco, and are inhaled by the smoker as part of the mainstream smoke. These oxidants lead to the production of secondary ROS by inflammatory and epithelial cells within the lung as part of an inflammatory immune response [3].

Local and systemic inflammation and oxidative stress are related to the pathophysiological changes in COPD. Inflammation occurs usually as a response to pathogens (bacteria, viruses) and/or inhalation of cigarette smoke and other noxious particles [4]. The oxidative stress associated with COPD is a result of either endogenous production of reactive oxygen species (ROS) by inflammatory cells, or due to the direct oxidative damage by the cigarette smoke [5,6]. Oxidative stress has a wide range of effects, one of which is telomere length shortening [7,8].

Telomeres are nucleoprotein structures at the end of the chromosomes that consist of the following hexameric tandem repeat: TTAGGG. Due to the replication end problem, the telomeres are shortened in each cell division. It has been found that when telomeres are shortened beyond a critical level (under 6000–8000 base pairs), the cell loses its ability to divide and becomes senescent or undergoes apoptosis [9,10]. In some cells, such as stem cells, an enzyme known as telomerase maintains the telomeres length (TL). The TL varies widely between individuals, and even between different cells in one organism, as there are variety of factors (endogenous and exogenous) that impact TL [11]. It has been found that leukocyte telomere length (LTL) decreases with age, and is associated with increased risk of age-related diseases, such as cardiovascular diseases, diabetes, rheumatoid arthritis, and COPD [12–14].

Inflammation and oxidative stress have been found to reflect on telomere length [15]. In an in vitro study, it has been shown that in endothelial cells, ROS decreases telomerase activity and the level of nuclear human telomerase reverse transcriptase (hTERT) [16]. On the other hand, reductions in oxidative stress and antioxidants have been shown to decrease the rate of telomere shortening and delay the beginning of senescence via mechanisms related to telomerase activity [11,16–18].

Keeping in mind that oxidative stress is a major factor in COPD pathogenesis and telomere shortening, it could be suggested that antioxidants may have plausible effects in the prevention of both. Indeed, antioxidants have been shown to improve the symptoms in COPD and delay ageing [5,19]. As one of the most important antioxidants in the body, we hypothesize that glutathione might reflect the LTL.

Glutathione S-transferases (GSTs) are a superfamily of enzymes that catalyze the conjugation of reduced glutathione (GSH) to a wide variety of exogenous and endogenous toxic compounds with electrophilic sites, including cigarette smoke and ROS, and protect DNA from oxidative damage. So far, GSTs have been classified into eight classes: α (GSTA), μ (GSTM), θ (GSTT), π (GSTP), σ (GSTS), κ (GSTK), o (GSTO) and τ (GSTZ) [20]. It has been found that most of the genes encoding GST isoenzymes are polymorphic. A greater degree of polymorphism has been reported for GSTM1 and GSTT1 genes as homozygous deletion results in the lack of the protein product and loss of enzymatic activity [21,22].
There is evidence that shorter telomeres and null variants of \textit{GSTM1} and \textit{GSTT1} are associated with increased risk of age-related diseases, including COPD \cite{13, 23, 24}.

In this study, we aimed to explore the link between the \textit{GSTM1} and \textit{GSTT1} null genotypes, total glutathione, LTL and the risk of COPD.

2. Methods and Materials

2.1. Patients and Controls

In our study were included 152 patients with COPD and 131 control individuals that were non-affected by any lung diseases. All patients and controls were from the region of Stara Zagora, Bulgaria. The recruitment of the patients was conducted in the Clinic of Internal Medicine, University Hospital, Trakia University, Stara Zagora, Bulgaria. All inclusion criteria for COPD were described in our previous study \cite{25}.

The available demographic and clinical data of the examined groups are presented in Table 1.

Table 1. Demographic and clinical data of COPD patients and controls.

| Characteristics                          | COPD Patients | Controls |
|------------------------------------------|---------------|----------|
| Number \((n = 152)\)                     |               | \((n = 131)\) |
| males \((75\%)\)                        | 114           | 61 \((46.6\%)\) |
| females \((25\%)\)                      | 38            | 70 \((53.4\%)\) |
| Age at the inclusion in the study        |               |          |
| mean \(\pm\) SD (years)                 | 66.6 \(\pm\) 4.9 | 59.3 \(\pm\) 11.69 |
| median (range) (years)                  | 67 (40–88)    | 60 (23–85) |
| Age at the diagnosis of the disease      |               |          |
| mean \(\pm\) SD (years)                 | 61.5 \(\pm\) 9.9 |          |
| median (range) (years)                  | 62 (34–86)    |          |
| Duration of the disease                 |               |          |
| mean \(\pm\) SD (years)                 | 5.26 \(\pm\) 5.4 |          |
| median (range) (years)                  | 4 (0–30)      |          |
| Smoking status \((n = 152)\)            |               | \((n = 131)\) |
| non-smokers \((30.2\%)\)               | 45            | 59 \((60.2\%)\) |
| ex-smokers \((44.3\%)\)                | 66            | 10 \((10.2\%)\) |
| current smokers \((25.5\%)\)           | 38            | 29 \((29.6\%)\) |
| Smoking habits (packs/year)             |               |          |
| mean \(\pm\) SD (years)                 | 31.6 \(\pm\) 14.1 | 16.4 \(\pm\) 10.7 |
| median (range)                          | 30 (5–70)     | 15 (5–50) |
| COPD stage \((n = 152)\)               |               |          |
| GOLD II \((48\%)\)                     | 73            |          |
| GOLD III \((45.4\%)\)                  | 69            |          |
| GOLD IV \((6.6\%)\)                    | 10            |          |
| FEV1 % pred.                            |               |          |
| mean \(\pm\) SD                        | 50.47 \(\pm\) 13.76 | 96.25 \(\pm\) 11.67 |
| FEV1/FVC%                                |               |          |
| mean \(\pm\) SD                        | 60.81 \(\pm\) 8.87 | 81.40 \(\pm\) 7.88 |

The protocol of the current study (number 10/05.06.2019) was issued by the ethics committee at the Medical Faculty of Trakia University, Stara Zagora, Bulgaria. Written informed consent was obtained from each of the participants before the study.

2.2. Isolation of DNA

The isolation of genomic DNA was performed using a commercial kit (GenElute™ mammalian genomic DNA miniprep kit, Sigma- G1N70, Merck KGaA, Darmstadt, Ger-
many). As described earlier, the purity of the isolated DNA was assessed spectrophotometrically [25].

2.3. Genotyping

The null polymorphisms in GSTM1 and GSTT1 were assessed using multiplex (duplex) PCR [26], which we modified, as described in detail in a previous study [27]. GSTP1 was chosen as a reference gene for assessing the amplification process and presence of sufficient amount of DNA template. The primers and the size of the amplification products, as well as the temperature profile of the PCR reactions, are provided in Table 2.

Table 2. Primer sequences, size of the PCR products, and temperature profile used in the multiplex (duplex) PCR for genotyping for null GSTM1 and GSTT1 polymorphisms.

| Gene   | Primers                                      | Size of the PCR Product |
|--------|----------------------------------------------|-------------------------|
| GSTP1  | F: 5′-ACC CCA GGG CTC TAT GGG AA-3′<br>R: 5′-TGA GGG CAC AAG CCC CT-3′ | 176 bp                  |
| GSTM1  | F: 5′-GAA CTC CCT GAA AAG CTA AAG C-3′<br>R: 5′-GTG GGG CTC AAA TAT ACG GTG G-3′ | 219 bp                  |
| GSTT1  | F: 5′-TTC CTT ACT GGT CCT CAC ATC TC-3′<br>R: 5′-TCA CGG GAT CAT GGC CAG CA-3′ | 459 bp                  |

Temperature profile of PCR

10 min at 94 °C-predenaturation<br>40 cycles of:<br>94 °C-1 min,<br>62 °C-30 s,<br>72 °C-1 min<br>7 min at 72 °C-final extension

As part of assessing the purity of the PCR reaction, positive and negative (blank) controls were included in all PCRs. We used, as positive controls, samples that in previous analyses were genotyped as GSTM1 non-null and GSTT1 non-null [27]. The negative controls were reactions performed without total DNA as a template. PCR products were analyzed on 2.5% agarose gel, stained with ethidium bromide, and documented with a gel documentation system (Syngene, Synoptics Ltd., Cambridge, UK).

2.4. Leukocyte Telomere Length (LTL) Measurement

The telomere length was measured using SYBR green qPCR method, described in detail previously [25].

2.5. Serum Total Glutathione Measurement

The total glutathione (GSSG + GSH) concentration was evaluated in serum deproteinized with 5% 5-sulfosalicylic acid. The applied method is a kinetic assay (Sigma, glutathione assay kit; CS0260) that measures the reduction in 5,5-dithiobis-(2-nitrobenzoic) acid (DTNB) by GSH to TNB, which is detected spectrophotometrically at 412 nm.

2.6. Statistical Analyses

Statistical analyses were performed using SPSS 16.0 for Windows (IBM, Chicago, IL). After assessing the normality of the distribution of the continuous variables, they were compared either by a Student’s t-test or one-way ANOVA with LSD post hoc analysis, or using a Mann–Whitney U test or Kruskal–Wallis H test, for those with normal and non-normal distributions, respectively. The correlations between the continuous variables were assessed using a Pearson’s correlation test.

The differences in genotype distribution between the patient and control groups were assessed with χ² tests in 2 × 2 contingency tables. The odds ratios (OR) and 95% confidence
intervals (CI) were obtained by applying the binary logistic regression. Outputs with 
$p < 0.05$ were considered statistically significant.

3. Results

The GSTM1 and GSTT1 null polymorphisms were analyzed in multiplex (duplex) PCR 
reactions, using GSTP1 as a reference gene in each of the reactions. In the electrophoresis 
gel, one individual that was homozygous for the GSTM1 null polymorphism (GSTM1 
null) had only one visible band of 176 bp of the PCR reaction products corresponding 
to the PCR product of the reference GSTP1 gene, while another person that carried one 
or two wildtype alleles of GSTM1 (GSTM1 non-null) had two bands: a 219-bp band 
of the GSTM1 PCR product and a 176-bp band of the GSTP1 reference gene (Figure 1).

Analogously, an individual with at least one wildtype GSTT1 allele (GSTT1 non-null) had, 
in the electrophoreotic gel, two PCR products: a band of 459 bp for GSTT1, and a band 
of 176 bp for the GSTP1 reference gene. In contrast, a person homozygous for the GSTT1 
null polymorphism (GSTT1 null) had, in the electrophoretic gel, only one PCR product of 
176 bp, corresponding to the GSTP1 reference gene.

![Figure 1. Genotyping of GSTM1 and GSTT1 by duplex PCRs. Non-null GSTM1 genotype individual 1 (M1+) and 3 (M1+); null GSTM1 genotype individual 2 (M1-) and 4 (M1-); non-null GSTT1 genotype individual 1 (T1+), 3 (T1+) and 4 (T1+); null GSTT1 genotype individual 2 (T1-); lines 1 and 2 (M1-0 and T1-0) are negative controls for GSTM1 and GSTT1 duplex PCRs; line 3 (marker) is a 100-bp DNA ladder (Thermo Fisher Scientific Inc, Waltham, MA, USA).](image)

The GSTM1 null genotypes were found to be more frequent in the COPD patient 
group, implying a 2.35-fold higher risk of COPD ($p < 0.000$, Table 3). For GSTT1, there was 
no significant difference of genotype distributions between patients and controls ($p = 0.192$, 
Table 3).

When we analyzed the combined effect of GSTM1 and GSTT1 null polymorphisms, 
we found a significant prevalence of at least one null genotype (either GSTM1 or GSTT1 
or both null genotypes simultaneously) in COPD patients compared to controls ($p = 0.027$, 
Table 3). Thus, individuals that carry at least one null variant have a 2.84-fold higher risk 
of developing COPD. The above associations of the effects as risk factors of GSTM1 null 
variant, or the presence of at least one null variant, remained significant after adjustment 
for sex and age (Table 3).

When analyzing the possible relationship between the LTL and the carrying of GSTM1 
or GSTT1 null variants, we found that patients that carry the GSTM1 null variant had shorter 
telomeres in circulating leucocytes compared to those carrying the non-null genotype 
(15,720 ± 1514.6 bp vs. 22,442 ± 1995.9 bp, $p = 0.008$, Figure 2). Interestingly, in the control 
group, those carrying the GSTM1 non-null genotype had shorter telomeres compared to
those with the null genotype (17,800 ± 2217.3 bp vs. 31,354 ± 5608.8 bp, p = 0.020, Figure 2). Although not significant, controls with the null GSTM1 variant were younger (57.40 ± 1.71 (SEM) years) than those with the non-null GSTM1 genotype (60.54 ± 1.31 (SEM) years, p = 0.174). In the patient group, mean age was comparable for the GSTM1 null variant and non-null variant carriers (66.51 ± 0.95 (SEM) years vs. 66.89 ± 1.29 (SEM) years, p = 0.777).

Table 3. Genotype of GSTM1 and GSTT1 gene polymorphism in patients with COPD and controls.

|            | COPD Patients | Controls | OR (95% CI), p-Value | OR (95% CI), p-Value (Adjusted for Sex and Age) |
|------------|---------------|----------|----------------------|-----------------------------------------------|
|            | n = 152       | n = 131  |                      |                                               |
| **GSTM1**  |               |          |                      |                                               |
| non-null   | 62            | 81       | 1.0 (reference)      | 1.0 (reference)                               |
| null       | 90            | 50       | 2.35 (1.46–3.79), p ≤ 0.000 | 2.49 (1.46–4.23), p = 0.001                  |
| **GSTT1**  |               |          |                      |                                               |
| non-null   | 117           | 110      | 1.0 (reference)      | 1.0 (reference)                               |
| null       | 31            | 20       | 1.46 (0.79–2.69), p = 0.192 | 1.39 (0.71–2.72), p = 0.337                  |
| **GSTM1 and GSTT1** | n = 149 | n = 130 |                      |                                               |
| both non-null | 131       | 124      | 1.0 (reference)      | 1.0 (reference)                               |
| at least one null | 18         | 6        | 2.84 (1.12–7.17), p = 0.027 | 2.39 (1.40–4.08), p = 0.001                  |

No association between LTL and GSTT1 was found, either in patients (non-null: 18,588 ± 1368.07 bp vs. null: 18,097 ± 3638.6 bp, p = 0.901), or in controls (non-null: 22,511 ± 2854.6 bp vs. null: 29,745 ± 9498 bp, p = 0.328).

A similar association as that found for the GSTM1 genotype and LTL was found when combining both GSTM1 and GSTT1. COPD patient carriers of at least one null variant had shorter telomeres (16,409 ± 1478.4 bp vs. 22,092 ± 2190 bp, p = 0.029, Figure 3). In controls, this was the opposite; individuals with the non-null genotype had shorter LTLs (16,370 ± 2358.6 bp vs. 29,666 ± 4664.2 bp, p = 0.027, Figure 3).
The serum levels of total glutathione were significantly higher in controls with the GSTM1 non-null genotype in comparison to the carriers of the null GSTM1 genotype (15.39 ± 2.01 ng/mL vs. 5.53 ± 0.85 ng/mL, \( p = 0.002 \), Figure 4). In COPD patients, we found no difference (non-null: 9.53 ± 2.27 ng/mL vs. null: 13.39 ± 2.26 ng/mL, \( p = 0.301 \)).

No association was found for GSTT1 and total glutathione, both in patients (null: 7.29 ± 1.54 ng/mL vs. non-null: 13.43 ± 2.07 ng/mL, \( p = 0.205 \)), and controls (null: 10.91 ± 4.15 ng/mL vs. non-null: 11.58 ± 2.06 ng/mL, \( p = 0.885 \)).

Controls with the non-null genotype of both GSTM1 and GSTT1 had higher total glutathione in serum in contrast with those carrying at least one null variant (15.72 ± 2.44 ng/mL vs. 7.71 ± 1.75 ng/mL, \( p = 0.018 \), Figure 5). In COPD patients, there was a lack of difference...
in the serum levels of total glutathione between the genotypes (non-null: $9.62 \pm 2.59$ ng/mL vs. at least one null: $13.15 \pm 2.15$ ng/mL, $p = 0.365$).

No association was found for GSTT1 and total glutathione, both in patients (null: $7.29 \pm 1.54$ ng/mL vs. non-null: $13.43 \pm 2.07$ ng/mL, $p = 0.205$), and controls (null: $10.91 \pm 4.15$ ng/mL vs. non-null: $11.58 \pm 2.06$ ng/mL, $p = 0.885$).

Controls with the non-null genotype of both GSTM1 and GSTT1 had higher total glutathione in serum in contrast with those carrying at least one null variant ($15.72 \pm 2.44$ ng/mL vs. $7.71 \pm 1.75$ ng/mL, $p = 0.018$, Figure 5). In COPD patients, there was a lack of difference in the serum levels of total glutathione between the genotypes (non-null: $9.62 \pm 2.59$ ng/mL vs. at least one null: $13.15 \pm 2.15$ ng/mL, $p = 0.365$).

We failed to find a correlation between serum total glutathione and LTL in COPD patients ($r = -0.005$, $p = 0.980$) and controls ($r = -0.273$, $p = 0.446$).

The concentration of total glutathione in the serum (ng/mL) and the LTL (bp) in controls and COPD patients are presented in Table 4.

### Table 4. Concentration of total glutathione in the serum (ng/mL) and the LTL (bp) in controls and COPD patients. Data are presented as mean ± SEM.

| Genotype                      | Total Glutathione | LTL               |
|-------------------------------|-------------------|-------------------|
|                               | Mean ± SEM (ng/mL)| Mean ± SEM (Base Pairs) |
| Controls Patients p-Value     | Controls Patients p-Value |
|-------------------------------|-------------------|-------------------|
| GSTM1 non-null                | $15.39 \pm 2.01$  | $17,800 \pm 2217.3$ | $22,442 \pm 1995.9$ | $0.020$  | $0.008$  |
| GSTM1 null                    | $5.53 \pm 0.85$   | $31,354 \pm 5608.8$ | $15,720 \pm 1514.6$ | $0.004$  | $0.353$  |
| GSTT1 non-null                | $11.58 \pm 2.06$  | $22,511 \pm 2854.6$ | $18,588 \pm 1368.1$ | $0.046$  | $0.046$  |
| GSTT1 null                    | $10.91 \pm 4.15$  | $29,745 \pm 9498$  | $18,097 \pm 3638.6$ | $0.004$  | $0.004$  |
| both GSTM1 and GSTT1 non-null | $15.72 \pm 2.44$  | $16,370 \pm 2358.6$ | $22,092 \pm 2190$  | $0.018$  | $0.018$  |
| G, both GSTM1 and GSTT1 at least one null | $7.71 \pm 1.75$ | $29,666 \pm 4664.2$ | $16,409 \pm 1478.4$ | $0.018$  | $0.018$  |

| p-value (GSTM1 non-null vs. null) | $0.002$  | $0.301$  | $0.020$  | $0.008$  |
| p-value (GSTT1 non-null vs. null) | $0.885$  | $0.205$  | $0.328$  | $0.901$  |
| p-value (both non-null vs. at least one null) | $0.018$  | $0.365$  | $0.027$  | $0.029$  |
4. Discussion

It is known that one of the factors involved in the pathogenesis of COPD is oxidative stress, as it might be the result of either the overproduction of ROS or impaired antioxidant defense systems (or both). One of the major triggers of ROS production and inflammation in COPD are cigarette smoking and inhalation of environmental and occupational pollutants (e.g., wood smoke, coal dust, etc.) [28].

Following inhalation of exogenous particles, inflammatory cells, including macrophages and neutrophils, accumulate in the lungs, generating a large amount of endogenous ROS in order to protect the lungs against exogenous pollutants via phagocytosis. However, in chronic inflammatory conditions, such as COPD, macrophages and neutrophils become a persistent source of oxidants, leading to tissue injury and further oxidative stress [29,30].

GSTs are enzymes that catalyze the conjugation of GSH with a variety of toxic compounds, including oxidative intermediates and ROS, and it has been found that they are expressed in the airway epithelium and alveolar macrophages [5,6,31,32]. Most of the genes encoding the GSTs are polymorphic, as the null variants, due to the homozygous deletions of the GSTM1 and GSTT1 genes, might result in the lack of GST-mu and GST-theta enzyme activity [21].

In our study, we found higher prevalence of the GSTM1 null variant and at least one null variant of either GSTM1 or GSTT1 in COPD patients. Based on the experimental studies of Seidegård et al. [33], as well as the results of Lee et al. [34], concerning the effects of the null variant of GSTM1 and GSTT1 genes on enzyme activity and enzyme protein levels, we suggest that the loss of enzymatic activity in COPD patients that carry the null GSTM1 variant results in altered antioxidant defense and the detoxification of ROS and their products. This additionally contributes to the pathological changes present in COPD due to oxidation and inflammation.

As mentioned above, in our study, we found that the GSTM1 null variant, as well as the presence of at least one null GSTM1 or GSTT1 variants, determines a more than twofold higher risk for developing COPD. However, the results published in the scientific literature on the association of GSTM1 and GSTT1 polymorphisms with COPD are rather controversial.

In accordance with our findings, higher frequencies of the GSTM1 null genotype in COPD patients and no significant differences between patients and controls for the GSTT1 null polymorphism have been reported for a Serbian population [35]. Conversely, Zidzik et al. reported no association between null GSTM1 and GSTT1 genotypes and the risk of COPD [36]. The same has been found for Croatian males with stable COPD [18]. Studies conducted in India [37], Taiwan [38], Korea [39] and Turkey [40] have also shown controversial results, which might be associated with population differences.

We should not underestimate the fact that many other enzymes and non-enzymatic antioxidants might also impact the progress of COPD. It is well known that the substrate specificities of the different isoenzymes of GSTs overlap. In our study, we did not explore the enzyme activity of GSTs, which might have helped us to take a closer look into the multifactorial pathogenesis of the disease. The fact that there is a large difference in the results from a variety of studies show that as well as the polymorphisms in GSTM1 and GSTT1, other factors such as epigenetic and posttranslational modifications might influence the function of the enzymes, and, furthermore, predisposition to the disease. In addition, we did not find any differences in the genotype distribution among patients with different severities of COPD (GOLD stages), suggesting the role of factors varying from the deletion polymorphisms of GSTM1 and GSTT1 in the progression of this disease.

The impaired antioxidant defense will reflect on different cellular structures [41], as telomeres are highly susceptible to oxidative stress. This notion was proven in in vitro and in vivo studies, which have reported that oxidative stress leads to the telomere shortening [42–44]. In this respect, it is not surprising that our COPD patients with the GSTM1 null variant, and those with at least one null GSTM1 or GSTT1 variant, had significantly shorter LTLs compared to those with non-null genotypes. Except the loss of enzymatic GST
activity that might be a result of the deletion polymorphisms in \textit{GSTM1} and/or \textit{GSTT1}, in COPD, there is increased production of ROS [5,6], which will additionally contribute to LTL shortening.

It has been proposed that short telomeres could contribute to inflammation associated with COPD by inducing senescence, which upregulates the secretion of inflammatory factors systemically [17].

Telomeres are rich in guanine, and thus, they are more sensitive to oxidative damage [44]. It has been found that a variety of environmental and behavioral factors associated with COPD (tobacco smoking, air pollution, etc.) that lead to oxidative stress are able to influence LTL [28,45,46]. Oxidation may lead to DNA damage, resulting in double- or single-strand DNA breaks that eventually lead to telomere shortening [44]. Telomere shortening triggers senescence and loss of replicative capacity, as LTL is inversely related to age, and has been found to be associated with increased risk of age-related diseases, including COPD [47–49]. Another finding that emphasizes the role of the oxidative stress in telomere shortening is that in women, the average telomere length is higher [50]. It is known that estrogen protects the body from ROS formation and acts as an antioxidant [51]. In our previous study, we also described such an association with the gender, and suggested that LTL might be influenced by age and sex [25].

\textit{GSTM1} and \textit{GSTT1} enzymes decrease oxidative damage and prevent induced genotoxic attacks on DNA [52]. Many studies have explored the role of \textit{GSTM1} and \textit{GSTT1} polymorphisms in the genotoxic damage and telomere length [53–55]. Interestingly, we found that the controls carrying the non-null \textit{GSTM1} genotype had shorter telomeres. Telomere metabolism is a very dynamic process that is controlled by genetic as well as environmental determinants, and is highly specific at the individual-level. In addition to oxidative stress and inflammation, there are a number of factors that reflect the length of telomeres, such as maternal exposures during pregnancy, age of the father at conception, physical activity, diet, ethnicity, etc. [11]. Sex might be a possible explanation for this result, as it is probable that estrogen or some other features have an impact on LTL rather than polymorphisms in \textit{GSTM1} and \textit{GSTT1}. In addition, another explanation for this peculiar observation for longer LTL in null \textit{GSTM1} controls might be age. Although the difference is not significant, the mean age of our controls with the null \textit{GSTM1} variant was lower than of controls with the non-null genotype.

In addition to shorter LTL, in \textit{GSTM1} non-null controls, the concentration of total glutathione was higher. This might be a compensatory mechanism reducing the risk of age-related diseases by preventing oxidative damage. Glutathione is an important intra- and extracellular component of the antioxidant defense system found in epithelial lining fluid and plasma [56]. GSH homeostasis plays an important role in the maintenance of the integrity of the lung epithelial barrier, as the inhaled noxious particles, together with endogenous ROS, may trigger a significant local and systemic inflammatory response typical of COPD [57]. Patients with chronic inflammatory lung diseases, such as COPD, have shown increased oxidative stress and decreased levels of glutathione, enhancing the inflammatory response [30].

Probably, by preventing oxidation in the lungs and systematically, GSH reduces the inflammatory response, and thus, even with shorter leucocyte telomeres, the carriers of the \textit{GSTM1} non-null genotype may not develop COPD.

Despite exhibiting interesting and statistically significant results, our study has some limitations. One of the limitations is that we used qPCR instead of the fluorescence in situ hybridization (FISH) method, which is considered more reliable. Other limitations are the small number of individuals with measured LTL and the predominance of females in the control group. Therefore, a larger study enrolling more COPD patients and controls is warranted in order to confirm our current observations and conclusions.
5. Conclusions

Finding reliable biomarkers for COPD may help in the prevention and control of disease. We should not underestimate the fact that many mediators and lifestyle factors can modulate the inflammatory response and telomere length. Furthermore, the results of the role of GSTM1 and GSTTI polymorphism, together with LTL, in the development and severity of COPD are still relatively diverse. However, according to our findings, GSTM1, but not GSTTI, null genotypes might play a role in leucocyte telomere shortening, and thus be involved in the pathogenesis of COPD.

Author Contributions: Conceptualization, T.V., T.T., S.Z.-N.; Methodology, T.V., T.T., S.Z.-N.; Software, T.T., D.V., I.M.; Data curation, D.D., T.V., D.V.; Validation, D.D., T.V.; Formal Analysis, T.V., T.T., D.V., D.D.; Investigation, T.V., T.T., S.Z.-N.; Resources, D.D., S.Z.-N.; Writing—Original Draft Preparation, T.V., T.V.; Writing—Review & Editing, S.Z.-N., T.V., I.M.; Visualization, T.T., D.V.; Supervision, T.V.; Project Administration, T.V.; Funding Acquisition, T.V., S.Z.-N. All authors have read and agreed to the published version of the manuscript.

Funding: Research Project 3/2019 by Medical Faculty, Trakia University, Stara Zagora, Bulgaria.

Institutional Review Board Statement: This work was approved by the Ethics committee at Medical Faculty, Trakia University, Stara Zagora, Bulgaria, number 10/05.06.2019.

Informed Consent Statement: Written informed consents were obtained from all participants before the surgical therapy and enrolling in the study.

Data Availability Statement: The date of this study is available as SPSS file when requested to the authors.

Acknowledgments: The authors are cordially thankful to the research nurse Mariana Peeva for her help in collecting the biological materials. This work was performed with the financial support of the Research Project 3/2019 by Medical Faculty, Trakia University, Stara Zagora, Bulgaria.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available online: https://goldcopd.org (accessed on 11 July 2022).
2. Barnes, P.J. Cellular and molecular mechanisms of asthma and COPD. Clin. Sci. 2017, 131, 1541–1558. [CrossRef] [PubMed]
3. Caliri, A.W.; Tommasi, S.; Besaratinia, A. Relationships among Smoking, Oxidative Stress, Inflammation, Macromolecular Damage, and Cancer. Mutat. Res. Rev. Mutat. Res. 2021, 787, 108365. [CrossRef] [PubMed]
4. Brightling, C.; Greening, N. Airway inflammation in COPD: Progress to precision medicine. Eur. Respir. J. 2019, 54, 1900651. [CrossRef] [PubMed]
5. Barnes, P.J. Oxidative stress-based therapeutics in COPD. Redox Biol. 2020, 33, 101544. [CrossRef] [PubMed]
6. Yoshida, M.; Minagawa, S.; Araya, J.; Sakamoto, T.; Hara, H.; Tsubouchi, K.; Hosaka, Y.; Ichikawa, A.; Saito, N.; Kadota, T.; et al. Involvement of cigarette smoke-induced epithelial cell ferroptosis in COPD pathogenesis. Nat. Commun. 2019, 10, 3145. [CrossRef] [PubMed]
7. Srinivas, N.; Rachakonda, S.; Kumar, R. Telomeres and Telomere Length: A General Overview. Cancers 2020, 12, 558. [CrossRef]
8. Lin, J.; Epel, E. Stress and telomere shortening: Insights from cellular mechanisms. Aging Res. Rev. 2022, 73, 101507. [CrossRef]
9. Turner, K.J.; Vasu, V.; Griffin, D.K. Telomere Biology and Human Phenotype. Cells 2019, 8, 73. [CrossRef]
10. Sławifiska, N.; Krupa, R. Molecular Aspects of Senescence and Organismal Ageing-DNA Damage Response, Telomeres, Inflammation and Chromatin. Int. J. Mol. Sci. 2021, 22, 590. [CrossRef]
11. Luikiewicz, M.; Bajser, J.; Kopczynski, P.; Barczak, W.; Rubis, B. Telomere length: How the length makes a difference. Mol. Biol. Rep. 2020, 47, 7181–7188. [CrossRef]
12. Salpea, K.D.; Talmud, P.J.; Cooper, J.A.; Maubaret, C.G.; Stephens, J.W.; Abelak, K.; Humphries, S.E. Association of telomere length with type 2 diabetes, oxidative stress and UCP2 gene variation. Atherosclerosis 2010, 209, 42–50. [CrossRef]
13. Córdoba-Lanús, E.; Cazorla-Rivero, S.; Espinoza-Jiménez, A.; de-Torres, J.P.; Pajares, M.J.; Aguirre-Jaime, A.; Celli, B.; Casanova, C. Telomere shortening and accelerated aging in COPD: Findings from the BODE cohort. Respir. Res. 2017, 18, 017-08547. [CrossRef]
14. Ormseth, M.J.; Solus, J.F.; Oser, A.M.; Bian, A.; Gebretsadik, T.; Shintani, A.; Raggi, P.; Stein, C.M. Telomere Length and Coronary Atherosclerosis in Rheumatoid Arthritis. J. Rheumatol. 2016, 43, 1469–1474. [CrossRef]
15. Hardikar, S.; Song, X.; Risques, R.A.; Montine, T.J.; Duggan, C.; Blount, P.L.; Reid, B.J.; Anderson, G.L.; Kratz, M.; White, E.; et al. Obesity and inflammation markers in relation to leukocyte telomere length in a cross-sectional study of persons with Barrett’s esophagus. BMC Obes. 2015, 2, 32. [CrossRef]
41. Paarvanova, B.; Tolekova, A.; Hadzhibozheva, P.; Georgiev, T.; Ivanov, I. Structural alteration in the membrane of erythrocytes from rats with Streptozotocin-induced diabetes. *Sci. Technol.* 2013, 3, 153–157.

42. De Rosa, M.; Johnson, S.A.; Opresko, P.L. Roles for the 8-Oxoguanine DNA Repair System in Protecting Telomeres From Oxidative Stress. *Front. Cell Dev. Biol.* 2021, 9, 758402. [CrossRef]

43. Boonekamp, J.J.; Bauch, C.; Mulder, E.; Verhulst, S. Does oxidative stress shorten telomeres? *Biol. Lett.* 2017, 13, 20170164. [CrossRef]

44. Reichert, S.; Stier, A. Does oxidative stress shorten telomeres in vivo? A review. *Biol. Lett.* 2017, 13, 20170463. [CrossRef]

45. Liu, B.; Maekawa, T.; Yoshida, K.; Ly, N.H.; Inoue, K.; Hasegawa, A.; Chatton, B.; Ogura, A.; Ishii, S. Telomere Shortening by Transgenerational Transmission of TNF-α-induced TERRA via ATF7. *Nucleic Acids Res.* 2019, 47, 283–298. [CrossRef]

46. Savale, L.; Chaouat, A.; Bastuji-Garin, S.; Marcos, E.; Boyer, L.; Maitre, B.; Sarri, M.; Houssset, B.; Weitzenblum, E.; Matrat, M.; et al. Shortened Telomeres in Circulating Leukocytes of Patients with Chronic Obstructive Pulmonary Disease. *Am. J. Respir. Crit. Care Med.* 2009, 179, 566–571. [CrossRef]

47. Soerensen, M.; Thinggaard, M.; Nygaard, M.; Dato, S.; Tan, Q.; Hjelmborg, J.; Andersen-Ranberg, K.; Stevnsner, T.; Bohr, V.A.; Kimura, M.; et al. Genetic variation in TERT and TERC and human leukocyte telomere length and longevity: A cross-sectional and longitudinal analysis. *Aging Cell* 2012, 11, 223–227. [CrossRef]

48. Amsellem, V.; Gary-Bobo, G.; Marcos, E.; Maitre, B.; Chaar, V.; Validire, P.; Stern, J.B.; Noureddine, H.; Sapin, E.; Rideau, D.; et al. Telomere dysfunction causes sustained inflammation in chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* 2011, 184, 1358–1366. [CrossRef]

49. Barnes, R.P.; Fouquerel, E.; Opresko, P.L. The impact of oxidative DNA damage and stress on telomere homeostasis. *Mech. Ageing Dev.* 2019, 177, 37–45. [CrossRef]

50. Dalgaard, C.; Benetos, A.; Verhulst, S.; Labat, C.; Kark, J.D.; Christensen, K.; Kimura, M.; Kyyvik, K.O.; Aviv, A. Telomere length dynamics in women and men: Menopause vs age effects. *Int. J. Epidemiol.* 2015, 44, 1688–1695. [CrossRef]

51. Vina, J.; Borras, C.; Gambini, J.; Sastre, J.; Pallardo, F.V. Why females live longer than males? Importance of the upregulation of longevity-associated genes by oestrogenic compounds. *FEBS Lett.* 2005, 579, 2541–2545. [CrossRef]

52. Eshkoor, S.A.; Marashi, S.J.; Ismail, P.; Rahman, S.A.; Mirinargesi, M.; Adon, M.Y.; Devan, R.V. Association of GSTM1 and GSTT1 with ageing in auto repair shop workers. *Genet. Mol. Res.* 2012, 11, 1486–1496. [CrossRef]

53. Pavanello, S.; Clonfero, E. Biological indicators of genotoxic risk and metabolic polymorphisms. *Mutat. Res.* 2000, 463, 285–308. [CrossRef]

54. Christiansen, L.; Brasch-Andersen, C.; Bathum, L.; Kruse, T.A.; Christensen, K. A longitudinal study of the effect of GSTT1 and GSTM1 gene copy number on survival. *Mech. Ageing Dev.* 2006, 127, 597–599. [CrossRef]

55. Sainger, R.N.; Shah, F.D.; Telang, S.D.; Shah, P.M.; Patel, P.S. Telomere attrition and telomerase activity are associated with GSTM1 polymorphism in oral cancer. *Cancer Biomark.* 2009, 5, 189–195. [CrossRef]

56. Rahman, I. Antioxidant therapies in COPD. *Int. J. Chron. Obstruct. Pulmon. Dis.* 2006, 1, 15–29. [CrossRef]

57. Sotgia, S.; Fois, A.G.; Paliogiannis, P.; Carru, C.; Mangoni, A.A.; Zinellu, A. Methodological Fallacies in the Determination of Serum/Plasma Glutathione Limit Its Translational Potential in Chronic Obstructive Pulmonary Disease. *Molecules* 2021, 26, 1572. [CrossRef]